Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Posttraumatic stress disorder (PTSD) is a prevalent condition that has been shown to be responsive to pharmacotherapy. Few head-to-head comparisons of medications used in the treatment of PTSD have been published. This 12-week, randomized, double-blind study compares the effectiveness, safety, and tolerability of nefazodone and sertraline for the treatment of PTSD. Thirty-seven male and female outpatients meeting DSM-IV criteria for PTSD were randomly assigned to receive nefazodone (maximum dose 600 mg/day; average dose 463 mg/day) or sertraline (maximum dose 200/day; average dose 153 mg/day). The primary outcome measures were the 17-item total severity score of the Clinician Administered PTSD Scale, Part 2 (CAPS-2) and the Clinical Global Impression Improvement Scale (CGI-I). Other assessments included the Davidson Trauma Scale (DTS), the Top-8 PTSD Rating Scale, Sheehan Disability Scale (SDS), Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Anxiety Scale (HAM-A), and Pittsburgh Sleep Quality Index (PSQI). Twenty-six subjects had at least one post-randomization CAPS-2 assessment and were therefore included in the data analysis. There were no statistically significant differences between treatment groups on any of the outcome measures. There was a significant effect for time in both groups, indicating an improvement in PTSD symptoms, depression, sleep, and quality of life over time. CAPS-2 scores for all of the PTSD symptom clusters decreased significantly over time. This study did not find significant differences in the effectiveness of nefazodone and sertraline for the treatment of PTSD. Larger trials are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale
Leon, A. C., Olfson, M., Portera, L., Farber, L., & Sheehan, D. V. (1997) · The International Journal of Psychiatry in Medicine · doi:10.2190/t8em-c8yh-373n-1uwd · Cited by 987 · cited 2×
“, 1989]; and 6) the Sheehan Disability Scale (SDS), a scale designed to rate function in a number of psychosocial domains [Leon et al., 1997].”
Rush, A. J., Armitage, R., Gillin, J. C., Yonkers, K. A., Winokur, A., Moldofsky, H., Vogel, G. W., Kaplita, S. B., Fleming, J. B., Montplaisir, J., et al. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00092-4 · Cited by 215 · cited 3×
“In addition to providing sustained relief of associated symptoms of anxiety and agitation, nefazodone has been shown to significantly improve sleep quality in depressed patients early in treatment [Armitage et al., 1994; Fawcett et al., 1995; Fontaine et al., 1994; Gillin et al., 1997; Rush et al., 1998].”
The effects of paroxetine and nefazodone on sleep: a placebo controlled trial
Sharpley, A. L., Williamson, D. J., Attenburrow, M. E. J., Pearson, G., Sargent, P., & Cowen, P. J. (1996) · Psychopharmacology · doi:10.1007/bf02246410 · Cited by 122
Gillin, J. C., Rapaport, M., Erman, M. K., Winokur, A., & Albala, B. J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0502 · Cited by 104
Armitage, R., Yonkers, K., Cole, D., & Rush, A. J. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199706000-00004 · Cited by 97
Cited by
What Is a “Mood Stabilizer”? An Evidence-Based Response
Bauer, M. S., & Mitchner, L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.3 · Cited by 862
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Pharmacotherapy for post traumatic stress disorder (PTSD)
Stein, D. J., Ipser, J. C., Seedat, S., Sager, C., & Amos, T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub2 · Cited by 519
Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis
Hoskins, M., Pearce, J., Bethell, A., Dankova, L., Barbui, C., Tol, W. A., van Ommeren, M., de Jong, J., Seedat, S., Chen, H., et al. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.148551 · Cited by 418
Forbes, D., Creamer, M., Phelps, A., Bryant, R., McFarlane, A., Devilly, G. J., Matthews, L., Raphael, B., Doran, C., Merlin, T., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701449161 · Cited by 335
Maher, M. J., Rego, S. A., & Asnis, G. M. (2006) · CNS Drugs · doi:10.2165/00023210-200620070-00003 · Cited by 334
Minimal clinically important change on the unified Parkinson's disease rating scale
Schrag, A., Sampaio, C., Counsell, N., & Poewe, W. (2006) · Movement Disorders · doi:10.1002/mds.20914 · Cited by 297
Pharmacotherapy of PTSD: premises, principles, and priorities.
Ravindran, L. N., & Stein, M. B. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.037 · Cited by 153
Hoskins, M. D., Bridges, J., Sinnerton, R., Nakamura, A., Underwood, J. F. G., Slater, A., Lee, M. R. D., Clarke, L., Lewis, C., Roberts, N. P., et al. (2021) · European Journal of Psychotraumatology · doi:10.1080/20008198.2020.1802920 · Cited by 127
“The characteristics of the included studies (Davidson et al., 2006; Kosten et al., 1991; McRae et al., 2004; Petrakis et al., 2012; Saygin et al., 2002; Spivak et al., 2006; Tucker et al., 2003) are detailed in Table 5.”
BackgroundMethodResultInfluentialBajor, L. A., Ticlea, A. N., & Osser, D. N. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.614483 · Cited by 76
Treatment of posttraumatic stress disorder: Focus on pharmacotherapy
Ehret, M. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.11.373 · Cited by 53
Effect of pharmacotherapy for anxiety disorders on quality of life: a meta-analysis
Hofmann, S. G., Wu, J. Q., Boettcher, H., & Sturm, J. (2014) · Quality of Life Research · doi:10.1007/s11136-013-0573-8 · Cited by 24
“Five studies included multiple separate drug conditions, so that a total of ten trials from these studies were analyzed as distinct trials [25, 38, 43, 44, 46].”
BackgroundAdvances in the management of treatment-resistant anxiety disorders
Lanouette, N. M., & Stein, M. B. (2010) · Focus · doi:10.1176/foc.8.4.foc501 · Cited by 15
Metadata
- Authors
- McRae, A. L., Brady, K. T., Mellman, T. A., Sonne, S. C., Killeen, T. K., Timmerman, M. A., & Bayles-Dazet, W.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2004
- Volume
- 19
- Issue
- 3
- Pages
- 190-196
- ISSN
- 1091-4269 (ISSN-L)
- 1520-6394
- OpenAlex
- W2030693702
- Cited by
- 60
- References
- 5
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.